The mechanism through which SCP could play a therapeutic role in NAFLD was confirmed by detecting the expression of the key targets in these metabolic pathways, including UGP2, UGDH, ACC, and FAS proteins. This evidence concerns the gene UGDH and metabolic dysfunction-associated steatotic liver disease.